Literature DB >> 18855831

Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone.

Marc Fishman1.   

Abstract

Background There has been increasing interest in the use of extended release injectable naltrexone for the treatment of opioid dependence. Case description We report a case of precipitated withdrawal in a 17-year-old adolescent female receiving extended release naltrexone (Vivitrol) for opioid dependence, following her third serial monthly dose of the medication, several days after using oxycodone with mild intoxication. Conclusions This case suggests that, in some circumstances, the opioid blockade may be overcome when naltrexone levels drop towards the end of the dosing interval, producing vulnerability to subsequent naltrexone-induced withdrawal. This may provide cautionary guidance for clinical management and dosing strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18855831     DOI: 10.1111/j.1360-0443.2008.02252.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  13 in total

Review 1.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

2.  Advances in opioid antagonist treatment for opioid addiction.

Authors:  Walter Ling; Larissa Mooney; Li-Tzy Wu
Journal:  Psychiatr Clin North Am       Date:  2012-04-10

Review 3.  Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available.

Authors:  Evgeny Krupitsky; Edwin Zvartau; George Woody
Journal:  Curr Psychiatry Rep       Date:  2010-10       Impact factor: 5.285

4.  Inhibitory transmission in the bed nucleus of the stria terminalis in male and female mice following morphine withdrawal.

Authors:  Brennon R Luster; Elizabeth S Cogan; Karl T Schmidt; Dipanwita Pati; Melanie M Pina; Kedar Dange; Zoé A McElligott
Journal:  Addict Biol       Date:  2019-04-09       Impact factor: 4.280

Review 5.  Opioid Use Disorders: Perioperative Management of a Special Population.

Authors:  Emine Nalan Ward; Aurora Naa-Afoley Quaye; Timothy E Wilens
Journal:  Anesth Analg       Date:  2018-08       Impact factor: 5.108

Review 6.  Antagonist Models for Relapse Prevention and Reducing HIV Risk.

Authors:  George E Woody; Evgeny Krupitsky; Edwin Zvartau
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-27       Impact factor: 4.147

7.  Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study.

Authors:  Brantley P Jarvis; Anthony DeFulio; Lauren Long; August F Holtyn; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  J Subst Abuse Treat       Date:  2016-12-24

Review 8.  Extended-release injectable naltrexone for opioid use disorder: a systematic review.

Authors:  Brantley P Jarvis; August F Holtyn; Shrinidhi Subramaniam; D Andrew Tompkins; Emmanuel A Oga; George E Bigelow; Kenneth Silverman
Journal:  Addiction       Date:  2018-03-24       Impact factor: 6.526

9.  Divergent behavioral responses in protracted opioid withdrawal in male and female C57BL/6J mice.

Authors:  Isabel M Bravo; Brennon R Luster; Meghan E Flanigan; Patric J Perez; Elizabeth S Cogan; Karl T Schmidt; Zoe A McElligott
Journal:  Eur J Neurosci       Date:  2019-10-06       Impact factor: 3.386

10.  Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users.

Authors:  Kelly E Dunn; Anthony Defulio; Jeffrey J Everly; Wendy D Donlin; Will M Aklin; Paul A Nuzzo; Jeannie-Marie S Leoutsakos; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  Exp Clin Psychopharmacol       Date:  2012-12-03       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.